Join our email list
Get exclusive deals and early access to new products.
Contact
BioLife Science
Email: info@biolife-science.com
Phone: 713-769-6498
At the intersection of regenerative medicine and hospitality, BioLife Science is building a scalable platform for personalized health and longevity.
Contact Investor RelationsThe global regenerative medicine category is expanding rapidly, supported by advances in stem cells, peptides, AI‑driven personalization, and consumer demand for proactive longevity care. BioLife Science is positioned to disrupt legacy wellness models with a high‑touch, data‑driven, membership experience that scales.
BioLife Science operates with transparent, disciplined governance — aligning clinical integrity with sustainable growth.
First centers opening in Houston, Austin, and Dallas, establishing the BioLife flagship experience.
Grow to 15 corporate‑owned clinics across major U.S. metros with standardized operating playbooks.
Roll out 30 franchise territories with a target of 45+ clinic openings per year. Begin Europe/Asia entry via master franchise and JV partnerships.
BioLife Science operates upscale wellness centers combining regenerative medicine, performance therapies, and concierge‑style care inside a membership model.
A blend of medical oversight, DNA & methylation‑anchored personalization, and hospitality‑level environments — designed for scale via corporate units and franchising.
Launch markets are Houston, Austin, and Dallas in 2025, followed by multi‑market U.S. expansion.
Members receive personalized plans, priority scheduling, concierge onboarding, and access to targeted protocols across recovery, performance, anti‑aging, and longevity.
Use the contact link above to reach Investor Relations for conversations regarding strategy, partnerships, or franchise interest.
This page includes forward‑looking statements regarding BioLife Science’s growth, market opportunities, and business strategy. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. Nothing on this page constitutes an offer to sell or a solicitation to buy securities.